Insider · CIK 0001709113
Sarah Cavanaugh
Files at CLDX (Celldex Therapeutics, Inc.). First filing -, latest -.
Sarah Cavanaugh files SEC Form 4 as officer at CLDX (Celldex Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sarah Cavanaugh has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +95,000 | $0.00 | $0 | 95,000 | Jun 29, 2026 |
| Jun 5, 2025 | CLDX Celldex Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +78,000 | $0.00 | $0 | 78,000 | Jun 9, 2025 |
Questions about Sarah Cavanaugh
Answered from the filings on this page, as of the latest one.
Is Sarah Cavanaugh buying or selling?
Sarah Cavanaugh has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sarah Cavanaugh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sarah Cavanaugh has 0.
Where does Sarah Cavanaugh file Form 4?
Sarah Cavanaugh has filed Form 4 at CLDX (Celldex Therapeutics, Inc.) as SVP OF CORP AFFAIRS & ADMIN.. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.